Equipoise lost: Prioritizing patient safety and early access to promising cancer therapies in clinical trial design by reimagining crossover

Kruti B Vora; Susan E. Bates

doi:10.1093/oncolo/oyag347

August 28, 2026The OncologistOpen Access

Equipoise lost: Prioritizing patient safety and early access to promising cancer therapies in clinical trial design by reimagining crossover

View Full Paper

Ask AI

Bookmark

Share

Key Points

To examine ethical and methodological challenges arising when clinical equipoise is lost, proposing reimagined crossover mechanisms to balance early therapy access with robust trial integrity.
Conceptual evaluation of ethical principles and clinical equipoise within randomized oncology clinical trials.
Analysis of crossover trial structures that permit control-arm participants to transition to experimental therapies upon disease progression or early efficacy demonstration.
Identifies that rigidly restricting crossover after clear experimental efficacy compromises participant safety and ethical obligations.
Proposes adaptive crossover strategies to ensure timely therapeutic access for participants without confounding critical survival endpoints.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Methodological analysis demonstrates the necessity of adaptive crossover designs in oncology trials, highlighting ethical pathways to preserve patient safety and treatment access.

Abstract

Kruti B Vora, Susan E Bates; Equipoise lost: Prioritizing patient safety and early access to promising cancer therapies in clinical trial design by reimagi

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vora et al. (2026) studied this question.

synapsesocial.com/papers/6a93f0f56c1a8fb52e79d781 https://doi.org/10.1093/oncolo/oyag347

View Full Paper

Ask AI

Bookmark

Share

Equipoise lost: Prioritizing patient safety and early access to promising cancer therapies in clinical trial design by reimagining crossover

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Equipoise lost: Prioritizing patient safety and early access to promising cancer therapies in clinical trial design by reimagining crossover

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading